vs
Side-by-side financial comparison of BRIGHT HORIZONS FAMILY SOLUTIONS INC. (BFAM) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
BRIGHT HORIZONS FAMILY SOLUTIONS INC. is the larger business by last-quarter revenue ($733.7M vs $708.5M, roughly 1.0× Medpace Holdings, Inc.). On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 8.8%). BRIGHT HORIZONS FAMILY SOLUTIONS INC. produced more free cash flow last quarter ($258.5M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 8.5%).
Bright Horizons Family Solutions Inc. is a United States–based child-care provider and is the largest provider of employer-sponsored child care. It also provides back-up child care and elder care, tuition program management, education advising, and student loan repayment programs. It is headquartered in Newton, Massachusetts.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
BFAM vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $733.7M | $708.5M |
| Net Profit | — | $135.1M |
| Gross Margin | 19.3% | — |
| Operating Margin | 6.2% | 21.6% |
| Net Margin | — | 19.1% |
| Revenue YoY | 8.8% | 32.0% |
| Net Profit YoY | — | 15.5% |
| EPS (diluted) | $0.38 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $733.7M | $708.5M | ||
| Q3 25 | $802.8M | $659.9M | ||
| Q2 25 | $731.6M | $603.3M | ||
| Q1 25 | $665.5M | $558.6M | ||
| Q4 24 | $674.1M | $536.6M | ||
| Q3 24 | $719.1M | $533.3M | ||
| Q2 24 | $670.1M | $528.1M | ||
| Q1 24 | $622.7M | $511.0M |
| Q4 25 | — | $135.1M | ||
| Q3 25 | $78.6M | $111.1M | ||
| Q2 25 | $54.8M | $90.3M | ||
| Q1 25 | $38.0M | $114.6M | ||
| Q4 24 | — | $117.0M | ||
| Q3 24 | $54.9M | $96.4M | ||
| Q2 24 | $39.2M | $88.4M | ||
| Q1 24 | $17.0M | $102.6M |
| Q4 25 | 19.3% | — | ||
| Q3 25 | 27.0% | — | ||
| Q2 25 | 25.0% | — | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | 24.2% | — | ||
| Q1 24 | 21.7% | — |
| Q4 25 | 6.2% | 21.6% | ||
| Q3 25 | 15.1% | 21.5% | ||
| Q2 25 | 11.8% | 20.9% | ||
| Q1 25 | 9.4% | 20.3% | ||
| Q4 24 | 7.2% | 23.4% | ||
| Q3 24 | 12.4% | 21.1% | ||
| Q2 24 | 10.3% | 19.9% | ||
| Q1 24 | 6.4% | 20.4% |
| Q4 25 | — | 19.1% | ||
| Q3 25 | 9.8% | 16.8% | ||
| Q2 25 | 7.5% | 15.0% | ||
| Q1 25 | 5.7% | 20.5% | ||
| Q4 24 | — | 21.8% | ||
| Q3 24 | 7.6% | 18.1% | ||
| Q2 24 | 5.8% | 16.7% | ||
| Q1 24 | 2.7% | 20.1% |
| Q4 25 | $0.38 | $4.65 | ||
| Q3 25 | $1.37 | $3.86 | ||
| Q2 25 | $0.95 | $3.10 | ||
| Q1 25 | $0.66 | $3.67 | ||
| Q4 24 | $0.50 | $3.67 | ||
| Q3 24 | $0.94 | $3.01 | ||
| Q2 24 | $0.67 | $2.75 | ||
| Q1 24 | $0.29 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $140.1M | $497.0M |
| Total DebtLower is stronger | $747.6M | — |
| Stockholders' EquityBook value | $1.3B | $459.1M |
| Total Assets | $3.9B | $2.0B |
| Debt / EquityLower = less leverage | 0.56× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $140.1M | $497.0M | ||
| Q3 25 | $116.6M | $285.4M | ||
| Q2 25 | $179.2M | $46.3M | ||
| Q1 25 | $112.0M | $441.4M | ||
| Q4 24 | $110.3M | $669.4M | ||
| Q3 24 | $109.9M | $656.9M | ||
| Q2 24 | $140.2M | $510.9M | ||
| Q1 24 | $63.7M | $407.0M |
| Q4 25 | $747.6M | — | ||
| Q3 25 | $747.5M | — | ||
| Q2 25 | $797.0M | — | ||
| Q1 25 | $872.7M | — | ||
| Q4 24 | $918.4M | — | ||
| Q3 24 | $925.7M | — | ||
| Q2 24 | $931.9M | — | ||
| Q1 24 | $938.1M | — |
| Q4 25 | $1.3B | $459.1M | ||
| Q3 25 | $1.4B | $293.6M | ||
| Q2 25 | $1.4B | $172.4M | ||
| Q1 25 | $1.3B | $593.6M | ||
| Q4 24 | $1.3B | $825.5M | ||
| Q3 24 | $1.4B | $881.4M | ||
| Q2 24 | $1.3B | $763.6M | ||
| Q1 24 | $1.2B | $671.5M |
| Q4 25 | $3.9B | $2.0B | ||
| Q3 25 | $3.9B | $1.8B | ||
| Q2 25 | $3.9B | $1.6B | ||
| Q1 25 | $3.8B | $1.9B | ||
| Q4 24 | $3.9B | $2.1B | ||
| Q3 24 | $3.9B | $2.1B | ||
| Q2 24 | $3.8B | $1.9B | ||
| Q1 24 | $3.8B | $1.8B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 0.73× | — | ||
| Q1 24 | 0.76× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $350.7M | $192.7M |
| Free Cash FlowOCF − Capex | $258.5M | $188.1M |
| FCF MarginFCF / Revenue | 35.2% | 26.6% |
| Capex IntensityCapex / Revenue | 12.6% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $402.4M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $350.7M | $192.7M | ||
| Q3 25 | $-17.6M | $246.2M | ||
| Q2 25 | $134.2M | $148.5M | ||
| Q1 25 | $86.2M | $125.8M | ||
| Q4 24 | $337.5M | $190.7M | ||
| Q3 24 | $-8.9M | $149.1M | ||
| Q2 24 | $109.4M | $116.4M | ||
| Q1 24 | $116.3M | $152.7M |
| Q4 25 | $258.5M | $188.1M | ||
| Q3 25 | $-42.4M | $235.5M | ||
| Q2 25 | $115.4M | $142.4M | ||
| Q1 25 | $70.9M | $115.8M | ||
| Q4 24 | $240.2M | $183.0M | ||
| Q3 24 | $-32.2M | $138.5M | ||
| Q2 24 | $86.8M | $103.5M | ||
| Q1 24 | $96.9M | $147.2M |
| Q4 25 | 35.2% | 26.6% | ||
| Q3 25 | -5.3% | 35.7% | ||
| Q2 25 | 15.8% | 23.6% | ||
| Q1 25 | 10.7% | 20.7% | ||
| Q4 24 | 35.6% | 34.1% | ||
| Q3 24 | -4.5% | 26.0% | ||
| Q2 24 | 13.0% | 19.6% | ||
| Q1 24 | 15.6% | 28.8% |
| Q4 25 | 12.6% | 0.6% | ||
| Q3 25 | 3.1% | 1.6% | ||
| Q2 25 | 2.6% | 1.0% | ||
| Q1 25 | 2.3% | 1.8% | ||
| Q4 24 | 14.4% | 1.4% | ||
| Q3 24 | 3.2% | 2.0% | ||
| Q2 24 | 3.4% | 2.4% | ||
| Q1 24 | 3.1% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | -0.22× | 2.22× | ||
| Q2 25 | 2.45× | 1.65× | ||
| Q1 25 | 2.26× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | -0.16× | 1.55× | ||
| Q2 24 | 2.79× | 1.32× | ||
| Q1 24 | 6.85× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BFAM
Segment breakdown not available.
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
